All News Notable Labs, Ltd.

Equities

NTBL

IL0012002452

End-of-day quote Nasdaq Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
1.25 ^USD	-15.54%		+31.58%	-33.86%

15/04	Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	MT
15/04	Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024	10/05	AQ
VASR BIOG : Notable Corporate Presentation	07/05	PU
Notable Labs Reports 2023 Financial Results and Provides a Business Update	15/04	AQ
Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	15/04	MT
Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	15/04	MT
Notable Labs Reports 2023 Financial Results and Provides a Business Update	12/04	AQ
VASR BIOG : AACR 2024 VOLA Poster	10/04	PU
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024	10/04	AQ
Notable Labs, Ltd. Presents the Design Plan for the Ppmp-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024	10/04	CI
VASR BIOG : AACR 2024 Poster	08/04	PU
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform	08/04	AQ
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay At AACR 2024 Expands the Potential of the Platform	08/04	CI
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform	05/03	AQ
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment	22/02	AQ
Notable Labs, Ltd. Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment	22/02	CI
Top Premarket Gainers	09/01	MT
JMP Securities Cuts Notable Labs' Price Target to $9 From $13, Keeps Market Outperform Rating	19/12	MT
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome	18/12	AQ
Notable Labs, Ltd. and CicloMed LLC Announces Initial Safety and Efficacy Data of Fosciclopirox and the Performance of PPMP	18/12	CI
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit	05/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Notable Labs, Ltd.

Equities

NTBL

IL0012002452

All News

Filters